Compare Novavax Inc (NVAX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Prospect Capital Corporation — how do they compare? Novavax Inc trades at $11.06 (market cap $1.85B), while Prospect Capital Corporation trades at $1.83 (market cap $984.89M). The key difference: Novavax Inc is the larger of the two by market cap, and Prospect Capital Corporation pays a 22.76% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Prospect Capital Corporation for 78 Days on average.
| NVAX | PSEC | |
|---|---|---|
Market Cap | $1.85B | $984.89M |
Volume | 8,362,562 | 10,087,405 |
Sector | Health | Financials |
52-Week High | $12.56 | $3.05 |
52-Week Low | $6.22 | $1.82 |
Typical Hold Time | 59 Days | 78 Days |
Enterprise Value | $1.43B | $2.74B |
Dividend Yield | — | 22.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
PSEC trades at $1.82, down 0.55% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has beaten EPS estimates for the last three quarters, though revenue and net income were negative in 2025. Recent news highlights dividend declarations and management commentary on market opportunities, but financial performance shows volatility with a sharp revenue decline in 2025.
The outlook is mixed; a low P/B ratio of 0.34 suggests potential undervaluation, but negative cash flow and inconsistent profitability pose risks. Analyst sentiment is cautious with a majority Hold rating. Key opportunities include dividend yield and earnings beats, while risks involve financial instability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
